CyPath Lung

bioAffinity Technologies (BIAF, BIAFW) secured financing through securities purchase agreements with investors, involving the sale of Series B Convertible Preferred Stock and warrants to purchase common stock in a private placement. They also reached a warrant exercise agreement, generating $253,000. These transactions aim to raise approximately $1.2 million for working capital and general corporate purposes, supporting the development and commercialization of their CyPath® Lung test, a non-invasive early lung cancer detection method with reported 92% sensitivity. WallachBeth Capital LLC acted as placement agent.